Hope for dravet syndrome: Long-Term safety trial of STK-001 underway
Disease control
Ongoing
This study looks at the long-term safety of an experimental drug called zorevunersen (STK-001) in 60 people with Dravet syndrome, a severe form of epilepsy. Participants must have completed a previous STK-001 study. The main goal is to check for side effects, while also tracking …
Phase: PHASE2 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control
Last updated May 11, 2026 20:41 UTC